ELSEVIER

Clinica Chimica Acta 279 (1999) 183–185

Author index

Volume 279 (1999)

Alhava, E., see Parviainen, M.T. **279**, 145
Argov, Z., see Lev, E.I. **279**, 107
Arnala, I., see Parviainen, M.T. **279**, 145
Ashkenazy, I., see Lev, E.I. **279**, 107

Baba, S., see Kinoshita, M. **279**, 15
Bachmair, F., Huber, Ch., Daxenbichler, G., Quantitation of gene expression by means of HPLC analysis of RT-PCR products **279**, 25
Bago, K., see Kinoshita, M. **279**, 15
Bogard, C., see Tchernitchko, D. **279**, 133
Bourrouillou, G., see Vergnes, H. **279**, 167
Brites, F.D., Cavallero, E., de Geitere, C., Nicolaïew, N., Jacotot, B., Rosseneu, M., Fruchart, J.-C., Wikinski, R.L., Castro, G.R., Abnormal capacity to induce cholesterol efflux and a new LpA-I pre-β particle in type 2 diabetic patients **279**, 1
Brühlmann, P., see Krähenbühl, S. **279**, 35

Calapoğlu, M., see Efe, H. **279**, 155
Calvas, P., see Vergnes, H. **279**, 167
Castro, G.R., see Brites, F.D. **279**, 1
Cavallero, E., see Brites, F.D. **279**, 1
Cozzone, P.J., see Torri, G.M. **279**, 77

Daxenbichler, G., see Bachmair, F. **279**, 25
de Geitere, C., see Brites, F.D. **279**, 1
Değer, O., see Efe, H. **279**, 155
Denier, C., see Vergnes, H. **279**, 167
Deybach, J.C., see Tchernitchko, D. **279**, 133

Efe, H., Değer, O., Kirci, D., Karahan, S.C., Örem, A., Calapoğlu, M., Decreased neutrophil antioxidative enzyme activities and increased lipid peroxidation in hyperlipoproteinemic human subjects **279**, 155
Endoh, T., Yagihashi, A., Tanemura, K., Nishinosono, S., Matsukawa, M., Miyao, N., Tsukamoto, T., Watanabe, N., False-negative rapid plasma reagin circle card test **279**, 179

Faraggi, D., see Lev, E.I. **279**, 107
Ferré-Masferrer, M., Fuentes-Arderiu, X., Puchal-Añé, R., Indirect reference limits estimated from patients' results by three mathematical procedures **279**, 97
Fruchart, J.-C., see Brites, F.D. **279**, 1
Fuentes-Arderiu, X., see Ferré-Masferrer, M. **279**, 97

Gouya, L., see Tchernitchko, D. **279**, 133
Grozdea, J., see Vergnes, H. **279**, 167
Gulian, J.-M., see Torri, G.M. **279**, 77

Hadama, T., see Kinoshita, M. **279**, 15
Hiyoshi, S., see Tsuboi, I. **279**, 175
Hoppeler, H., see Krähenbühl, S. **279**, 35
Hoshino, H., see Takahashi, M. **279**, 69
Huber, Ch., see Bachmair, F. **279**, 25

Ida, H., see Tsuboi, I. **279**, 175
Imafuku, Y., see Ozawa, Y. **279**, 125
Inoue, M., see Meshitsuka, S. **279**, 47
Ishihara, Y., see Tatara, T. **279**, 117
Itoh, K., see Utsumi, K. **279**, 55
Iwao, Y., see Tatara, T. **279**, 117

Jääskeläinen, K., see Parviainen, M.T. **279**, 145
Jacotot, B., see Brites, F.D. **279**, 1

Karahan, S.C., see Efe, H. **279**, 155
Kase, R., see Utsumi, K. **279**, 55
Katagiri, Y., see Utsumi, K. **279**, 55

PII: S009-8981(98)00204-6

Kinoshita, M., Nakamura, J., Kusaka, H., Hadama, T., Bago, K., Kitajima, M., Baba, S., Automated and simultaneous identification of microsatellite instability by fluorescence-based polymerase chain reaction (PCR) in four loci **279**, 15
Kirci, D., see Efe, H. **279**, 155
Kitajima, M., see Kinoshita, M. **279**, 15
Koeda, T., see Meshitsuka, S. **279**, 47
Kotani, M., see Utsumi, K. **279**, 55
Krähenbühl, S., Willer, B., Brühlmann, P., Hoppeler, H., Stucki, G., Carnitine homeostasis in patients with rheumatoid arthritis **279**, 35
Kröger, H., see Parviainen, M.T. **279**, 145
Kusaka, H., see Kinoshita, M. **279**, 15
Kushida, K., see Takahashi, M. **279**, 69

Lamoril, J., see Tchernitchko, D. **279**, 133
Lev, E.I., Tur-Kaspa, I., Ashkenazy, I., Reiner, A., Faraggi, D., Shemer, J., Argov, Z., Distribution of serum creatine kinase activity in young healthy persons **279**, 107

Matsukawa, M., see Endoh, T. **279**, 179
Matsumoto, K., see Ozawa, Y. **279**, 125
Meshitsuka, S., Inoue, M., Seki, A., Koeda, T., Takeshita, K., Screening of urine by one-dimensional and pulsed-field gradient two-dimensional ^{1}H NMR spectroscopy: intoxication by propylene glycol in an infant patient **279**, 47
Miura, Y., see Ozawa, Y. **279**, 125
Miyao, N., see Endoh, T. **279**, 179
Mizuoka, K., see Tsuboi, I. **279**, 175

Nakamura, J., see Kinoshita, M. **279**, 15
Nakayama, I., see Tsuboi, I. **279**, 175
Nicolaïew, N., see Brites, F.D. **279**, 1
Nishi, S., see Ozawa, Y. **279**, 125
Nishinosono, S., see Endoh, T. **279**, 179
Nonomiya, T., see Tsuboi, I. **279**, 175
Nordmann, Y., see Tchernitchko, D. **279**, 133

Oguchi, T., see Utsumi, K. **279**, 55
O'Hara, K., see Tsuboi, I. **279**, 175
Ohkochi, S., see Tatara, T. **279**, 117
Örem, A., see Efe, H. **279**, 155
Ozawa, T., see Utsumi, K. **279**, 55
Ozawa, Y., Sato, S., Matsumoto, K., Nishi, S., Shishido, S., Imafuku, Y., Miura, Y., Yoshida, H., Determination of potassium flux activity of viable human erythrocytes by measuring the release-influx ratio **279**, 125

Parviainen, M.T., Jääskeläinen, K., Kröger, H., Arnala, I., Alhava, E., Urinary bone resorption markers in monitoring treatment of symptomatic osteoporosis **279**, 145
Puchal-Añé, R., see Ferré-Masferrer, M. **279**, 97
Puy, H., see Tchernitchko, D. **279**, 133

Reiner, A., see Lev, E.I. **279**, 107
Robreau, A.M., see Tchernitchko, D. **279**, 133
Rosipal, R., see Tchernitchko, D. **279**, 133
Rosseneu, M., see Brites, F.D. **279**, 1

Sakuraba, H., see Utsumi, K. **279**, 55
Sato, S., see Ozawa, Y. **279**, 125
Sawai, T., see Tsuboi, I. **279**, 175
Seki, A., see Meshitsuka, S. **279**, 47
Shemer, J., see Lev, E.I. **279**, 107
Shigenobu, F., see Tsuboi, I. **279**, 175
Shimizu, M., see Tsuboi, I. **279**, 175
Shimmoto, M., see Utsumi, K. **279**, 55
Shishido, S., see Ozawa, Y. **279**, 125
Stucki, G., see Krähenbühl, S. **279**, 35

Takahashi, M., Hoshino, H., Kushida, K., Measurements of urinary nonisomerized form of type I collagen degradation products (α-CTx) in aging, menopause, and osteoporosis with fractures **279**, 69
Takeda, J., see Tatara, T. **279**, 117
Takeshita, K., see Meshitsuka, S. **279**, 47
Tanemura, K., see Endoh, T. **279**, 179
Taniguchi, K., see Tsuboi, I. **279**, 175
Tanoue, K., see Utsumi, K. **279**, 55
Tatara, T., Iwao, Y., Takeda, J., Ishihara, Y., Ohkochi, S., Uedaira, H., Proton nuclear magnetic resonance spectroscopy of urine for rapid multicomponent analysis of intraoperative cellular metabolites **279**, 117
Tchernitchko, D., Lamoril, J., Puy, H., Robreau, A.M., Bogard, C., Rosipal, R., Gouya, L., Deybach, J.C., Nordmann, Y., Evaluation of mutation screening by heteroduplex analysis in acute intermittent porphyria: comparison with denaturing gradient gel electrophoresis **279**, 133
Torri, G.M., Torri, J., Gulian, J.-M., Vion-Dury, J., Viout, P., J. Cozzone, P., Magnetic resonance spectroscopy of serum and acute-phase proteins revisited: a multiparametric statistical analysis of metabolite variations in inflammatory, infectious and miscellaneous diseases **279**, 77
Torri, J., see Torri, G.M. **279**, 77
Tsuboi, I., Ida, H., Yoshikawa, E., Hiyoshi, S., Yamaji, E., Nakayama, I., O'Hara, K., Nonomiya, T., Shigenobu, F., Taniguchi, K., Shimizu, M., Sawai, T., Mizuoka, K., Uptake of [^{3}H]-fosfomycin into cells of enterohemorrhagic

Escherichia coli O157 and E. coli non-O157 **279**, 175
Tsukamoto, T., see Endoh, T. **279**, 179
Tur-Kaspa, I., see Lev, E.I. **279**, 107

Uedaira, H., see Tatara, T. **279**, 117
Utsumi, K., Itoh, K., Kase, R., Shimmoto, M., Yamamoto, N., Katagiri, Y., Tanoue, K., Kotani, M., Ozawa, T., Oguchi, T., Sakuraba, H., Urinary excretion of the vitronectin receptor (integrin $\alpha_v\beta_3$) in patients with Fabry disease **279**, 55

Vergnes, H., Grozdea, J., Denier, C., Bourrouillou, G., Calvas, P., Expression of a liver/bone–intestinal hybrid of alkaline phosphatase in neutrophils of Down's syndrome patients **279**, 167
Vion-Dury, J., see Torri, G.M. **279**, 77
Viout, P., see Torri, G.M. **279**, 77

Watanabe, N., see Endoh, T. **279**, 179
Wikinski, R.L., see Brites, F.D. **279**, 1
Willer, B., see Krähenbühl, S. **279**, 35

Yagihashi, A., see Endoh, T. **279**, 179
Yamaji, E., see Tsuboi, I. **279**, 175
Yamamoto, N., see Utsumi, K. **279**, 55
Yoshida, H., see Ozawa, Y. **279**, 125
Yoshikawa, E., see Tsuboi, I. **279**, 175

ELSEVIER

Clinica Chimica Acta 279 (1999) 187–189

Subject index

Volume 279 (1999)

Acute phase proteins; MRS spectroscopy; Serum proteins; Principal component analysis; Inflammation **279**, 77

Aging; Human erythrocytes; K^+ flux; Release-influx ratio; Na^+/K^+-exchanging ATPase **279**, 125

AIP, acute intermittent porphyria; PBGD, porphobilinogen deaminase; DDGE, denaturing gradient gel electrophoresis; HA, heteroduplex analysis **279**, 133

Alcohol; Creatine kinase; Myoglobin; Physical activity; BMI **279**, 107

Alkaline phosphatase; Hybrid isoenzyme; Neutrophils; Down's syndrome **279**, 167

Antioxidants; Hyperlipoproteinemia; Antioxidative enzymes; Lipid peroxidation; Neutrophil **279**, 155

Antioxidative enzymes; Hyperlipoproteinemia; Antioxidants; Lipid peroxidation; Neutrophil **279**, 155

Apolipoprotein A-I; Type 2 diabetes; Postprandial lipemia; Cholesterol efflux; Pre-β-HDL **279**, 1

Autosequencer; Microsatellite instability; Replication error; Microsatellite repeats; Loss of heterozygosity **279**, 15

BMI; Creatine kinase; Myoglobin; Physical activity; Alcohol **279**, 107

Bone marker; Bone resorption; Vertebral fracture; Hip fracture **279**, 69

Bone resorption; Bone marker; Vertebral fracture; Hip fracture **279**, 69

Carnitine; Rheumatoid arthritis; Muscle strength; Fatty acid metabolism; Carnitine palmitoyltransferase **279**, 35

Carnitine palmitoyltransferase; Rheumatoid arthritis; Muscle strength; Fatty acid metabolism; Carnitine **279**, 35

Cholesterol efflux; Type 2 diabetes; Postprandial lipemia; Apolipoprotein A-I; Pre-β-HDL **279**, 1

Creatine kinase; Myoglobin; Physical activity; BMI; Alcohol **279**, 107

DDGE, denaturing gradient gel electrophoresis; AIP, acute intermittent porphyria; PBGD, porphobilinogen deaminase; HA, heteroduplex analysis **279**, 133

Deoxypyridoline crosslinks; Fracture; Hormone therapy; N-telopeptide of Type I collagen; Osteoporosis; Postmenopausal women **279**, 145

Down's syndrome; Alkaline phosphatase; Hybrid isoenzyme; Neutrophils **279**, 167

Enterohemorrhagic *Escherichia coli*; O157; Uptake; Fosfomycin **279**, 175

PII: S009-8981(98)00205-8

Fatty acid metabolism; Rheumatoid arthritis; Muscle strength; Carnitine; Carnitine palmitoyltransferase **279**, 35

Fosfomycin; Enterohemorrhagic *Escherichia coli*; O157; Uptake **279**, 175

Fracture; Deoxypyridoline crosslinks; Hormone therapy; N-telopeptide of Type I collagen; Osteoporosis; Postmenopausal women **279**, 145

Gene expression; Quantitation; Reverse transcription–polymerase chain reaction; HPLC analysis **279**, 25

Globotriaosylceramide; MFabry disease; Vitronectin receptor; Vitronectin **279**, 55

^{1}H NMR; Propylene glycol; PFG–DQF–COSY; Intoxication; Urine **279**, 47

HA, heteroduplex analysis; AIP, acute intermittent porphyria; PBGD, porphobilinogen deaminase; DDGE, denaturing gradient gel electrophoresis **279**, 133

Hip fracture; Bone marker; Bone resorption; Vertebral fracture **279**, 69

Hormone therapy; Deoxypyridoline crosslinks; Fracture; N-telopeptide of Type I collagen; Osteoporosis; Postmenopausal women **279**, 145

HPLC analysis; Quantitation; Gene expression; Reverse transcription–polymerase chain reaction **279**, 25

Human erythrocytes; K^+ flux; Release-influx ratio; Na^+/K^+-exchanging ATPase; Aging **279**, 125

Hybrid isoenzyme; Alkaline phosphatase; Neutrophils; Down's syndrome **279**, 167

Hyperlipoproteinemia; Antioxidative enzymes; Antioxidants; Lipid peroxidation; Neutrophil **279**, 155

Inflammation; MRS spectroscopy; Serum proteins; Acute phase proteins; Principal component analysis **279**, 77

Intoxication; Propylene glycol; PFG–DQF–COSY; ^{1}H NMR; Urine **279**, 47

K^+ flux; Human erythrocytes; Release-influx ratio; Na^+/K^+-exchanging ATPase; Aging **279**, 125

Lipid peroxidation; Hyperlipoproteinemia; Antioxidative enzymes; Antioxidants; Neutrophil **279**, 155

Loss of heterozygosity; Microsatellite instability; Replication error; Autosequencer; Microsatellite repeats **279**, 15

Metabolism; Nuclear magnetic resonance; Proton; Surgery; Urine **279**, 117

MFabry disease; Globotriaosylceramide; Vitronectin receptor; Vitronectin **279**, 55

Microsatellite instability; Replication error; Autosequencer; Microsatellite repeats; Loss of heterozygosity **279**, 15

Microsatellite repeats; Microsatellite instability; Replication error; Autosequencer; Loss of heterozygosity **279**, 15

MRS spectroscopy; Serum proteins; Acute phase proteins; Principal component analysis; Inflammation **279**, 77

Muscle strength; Rheumatoid arthritis; Fatty acid metabolism; Carnitine; Carnitine palmitoyltransferase **279**, 35

Myoglobin; Creatine kinase; Physical activity; BMI; Alcohol **279**, 107

N-telopeptide of Type I collagen; Deoxypyridoline crosslinks; Fracture; Hormone therapy; Osteoporosis; Postmenopausal women **279**, 145

Na^+/K^+-exchanging ATPase; Human erythrocytes; K^+ flux; Release-influx ratio; Aging **279**, 125

Neutrophil; Hyperlipoproteinemia; Antioxidative enzymes; Antioxidants; Lipid peroxidation **279**, 155

Neutrophils; Alkaline phosphatase; Hybrid isoenzyme; Down's syndrome **279**, 167

Nuclear magnetic resonance; Metabolism; Proton; Surgery; Urine **279**, 117

O157; Enterohemorrhagic *Escherichia coli*; Uptake; Fosfomycin **279**, 175

Osteoporosis; Deoxypyridoline crosslinks; Fracture; Hormone therapy; N-telopeptide of Type I collagen; Postmenopausal women **279**, 145

Patients' results; Reference values; Statistical methods **279**, 97

PBGD, porphobilinogen deaminase; AIP, acute intermittent porphyria; DDGE, denaturing gradient gel electrophoresis; HA, heteroduplex analysis **279**, 133

PFG–DQF–COSY; Propylene glycol; ^{1}H NMR; Intoxication; Urine **279**, 47

Physical activity; Creatine kinase; Myoglobin; BMI; Alcohol **279**, 107

Postmenopausal women; Deoxypyridoline crosslinks; Fracture; Hormone therapy; N-telopeptide of Type I collagen; Osteoporosis **279**, 145

Postprandial lipemia; Type 2 diabetes; Cholesterol efflux; Apolipoprotein A-I; Pre-β-HDL **279**, 1

Pre-β-HDL; Type 2 diabetes; Postprandial lipemia; Cholesterol efflux; Apolipoprotein A-I **279**, 1

Principal component analysis; MRS spectroscopy; Serum proteins; Acute phase proteins; Inflammation **279**, 77

Propylene glycol; PFG–DQF–COSY; ^{1}H NMR; Intoxication; Urine **279**, 47

Proton; Nuclear magnetic resonance; Metabolism; Surgery; Urine **279**, 117

Quantitation; Gene expression; Reverse transcription–polymerase chain reaction; HPLC analysis **279**, 25

Rapid plasma reagin (RPR) circle card test; Syphilis **279**, 179

Reference values; Statistical methods; Patients' results **279**, 97

Release-influx ratio; Human erythrocytes; K^+ flux; Na^+/K^+-exchanging ATPase; Aging **279**, 125

Replication error; Microsatellite instability; Autosequencer; Microsatellite repeats; Loss of heterozygosity **279**, 15

Reverse transcription–polymerase chain reaction; Quantitation; Gene expression; HPLC analysis **279**, 25

Rheumatoid arthritis; Muscle strength; Fatty acid metabolism; Carnitine; Carnitine palmitoyltransferase **279**, 35

Serum proteins; MRS spectroscopy; Acute phase proteins; Principal component analysis; Inflammation **279**, 77

Statistical methods; Reference values; Patients' results **279**, 97

Surgery; Nuclear magnetic resonance; Metabolism; Proton; Urine **279**, 117

Syphilis; Rapid plasma reagin (RPR) circle card test **279**, 179

Type 2 diabetes; Postprandial lipemia; Cholesterol efflux; Apolipoprotein A-I; Pre-β-HDL **279**, 1

Uptake; Enterohemorrhagic *Escherichia coli*; O157; Fosfomycin **279**, 175

Urine; Nuclear magnetic resonance; Metabolism; Proton; Surgery **279**, 117

Urine; Propylene glycol; PFG–DQF–COSY; ^{1}H NMR; Intoxication **279**, 47

Vertebral fracture; Bone marker; Bone resorption; Hip fracture **279**, 69

Vitronectin receptor; MFabry disease; Globotriaosylceramide; Vitronectin **279**, 55

Vitronectin; MFabry disease; Globotriaosylceramide; Vitronectin receptor **279**, 55